Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder

Journal of Clinical Psychiatry

Volumn 60, Issue 6, 1999, Pages 400-406

  Versiani, Marcio ^a   Mehilane, Lembit ^d   Gaszner, Peter ^b   Arnaud Castiglioni, René ^c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^c Centre Hospitalier Valvert   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; FLUOXETINE; PLACEBO; REBOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REMISSION; SCORING SYSTEM; TACHYCARDIA; TREATMENT OUTCOME; URINE RETENTION;

EID: 0033063549     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0610     Document Type: Article

References (35)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
2. Angst J. How recurrent and predictable is depressive illness? In: Montgomery S, Rouillon F, eds. Perspectives in Psychiatry, vol 3: Long-Term Treatment of Depression. New York, NY: John Wiley; 1992:1-13
3. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997;54:989-991
4. Kamlet MS, Paul N, Greenhouse J, et al. Cost utility of maintenance treatment for recurrent depression. Control Clin Trials 1995;16:17-40
5. Kraepelin E. Manic-Depressive Insanity and Paranoia. Robertson GM, ed. Barclay RM, trans. Edinburgh, Scotland: E & S Livingstone; 1921
6. Angst J. The course of affective disorders. Psychopathology 1986;19 (suppl 2):47-52
7. Solomon DA, Keller M, Leon AC, et al. Recovery from major depression: a 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry 1997;54:1001-1006
8. Prien RF, Kupfer DJ. Continuation therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 1986;143:18-23
9. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992;305:1198-1202
10. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 1993;7:19-23
11. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52 (5, suppl):28-34
12. Robinson DS, Lerfald SC, Bennett B, et al. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 1991;27(1):31-39
13. Task Force of the Collegium Internationale Neuro-Psychopharmacologicum. Impact of neuropharmacology in the 1990s: strategies for the therapy of depressive illness. Eur Neuropsychopharmacol 1993;3:153-156
14. Feighner JP. Compliance and quality of response are major contributors to cost effective antidepressant therapy. Hum Psychopharmacol 1994;9 (suppl 1):S21-S23
15. Nelson JC. Safety and tolerabiliry of the new antidepressants. J Clin Psychiatry 1997;58(suppl 6):26-31
16. Montgomery SA. Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 1997;7(suppl 1):S3-S9
17. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychophannacol 1998;13:S29-S39
18. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychophannacol 1997;11(suppl 4):S9-S15
19. Riva M, Brunello N, Rovescalli AC, et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev 1989;1:243-253
20. Wong EHF, Graveel CR, Kagey ML, et al. Pharmacological selectivity of reboxetine: a selective noradrenaline reuptake inhibitor (NARI) [poster]. Presented at the 35th annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1997; Waikoloa, Hawaii
21. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997;7(suppl 1):S37-S47
22. Montgomery SA, Montgomery DB. Prophylactic treatment in recurrent unipolar depression. In: Montgomery S, Rouillon F, eds. Perspectives in Psychiatry, vol 3: Long-Term Treatment of Depression. New York, NY: John Wiley; 1992:53-79
23. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989;46:46-51
24. Committee for Proprietary Medicinal Products. Guidelines on psychotropic drugs for the EC. Eur Neuropsychopharmacol 1994;4:61-77
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987:213-233
27. Ban TA. CODE DD: Composite Diagnostic Evaluation of Depressive Disorders. Brentwood: JM Productions Inc; 1987
28. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
29. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
30. Zung WWK. A serf-rating depression scale. Arch Gen Psychiatry 1965;12: 52-70
31. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley & Sons; 1980:16-19
32. Lavori PW, Dawson R, Mueller TB. Causal estimation of time-varying treatment effects in observational studies: application to depressive disorder. Stat Med 1994;13:1089-1100
33. Mindham RHS, Howland C, Shepherd M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973;3:5-17
34. Montgomery SA. Antidepressants in long-term treatment. Annu Rev Med 1994;45:447-457
35. Kupfer DJ. Management of recurrent depression. J Clin Psychiatry 1993; 54:29-33